Get the Stockscreener App
1.21
1.63%
-0.02
Pre-market:
1.24
0.03
+2.48%
Entera Bio Ltd stock is traded at $1.21, with a volume of 86,064.
It is down -1.63% in the last 24 hours and down -3.97% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
See More
Previous Close:
$1.23
Open:
$1.25
24h Volume:
86,064
Relative Volume:
0.57
Market Cap:
$59.64M
Revenue:
$42,000
Net Income/Loss:
$-12.38M
P/E Ratio:
-4.5938
EPS:
-0.2634
Net Cash Flow:
$-9.61M
1W Performance:
+0.83%
1M Performance:
-3.97%
6M Performance:
-41.83%
1Y Performance:
-34.95%
1-Day Range:
$1.17
$1.25
1-Week Range:
$1.15
$1.25
52-Week Range:
$0.91
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.21 | 59.64M | 42,000 | -12.38M | -9.61M | -0.2634 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
ENTX SEC FilingsEntera Bio Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Entera Bio Ltd. (ENTX) Presents at Endocrine Society's Annual Meeting (ENDO 2026)Slideshow - Seeking Alpha
Entera Bio presents Phase 1 data on single-tablet EB613 - Investing.com
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) - Yahoo Finance
Entera Bio (ENTX) Slides 4.1% as Selling Pressure Tests Key Support at $1.11Long Term Entry Picks - newsline.com
ENTX Q1 2026 Earnings: Surprise EPS Beat as Operating Loss NarrowsEarnings Beat Alert - newsline.com
ENTX | Entera Bio Ltd. Ordinary Executive Compensation - Quiver Quantitative
Entera Bio (ENTX) Holds Steady at $1.22 as Stock Consolidates Near SupportElliott Wave Count - newsline.com
[ARS] Entera Bio Ltd. SEC Filing - Stock Titan
Entera Bio (NASDAQ: ENTX) 2026 proxy seeks board, equity plan and share capital approvals - Stock Titan
Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX) - TipRanks
Entera Bio Q1 2026 Earnings: Wider Loss Narrows on EPS Beat, Yet Shares SlideStrong Earnings Momentum - newsline.com
ENTX Q1 2026 Earnings: Better-than-Expected Losses Reflect Clinical ProgressAdjusted Earnings Analysis - The Legal Advocate
Entera Bio presents clinical data on osteoporosis candidate By Investing.com - Investing.com Nigeria
Entera Bio presents clinical data on osteoporosis candidate - Investing.com
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for OsteoporosisSingle Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation - The Manila Times
Experimental osteoporosis pill gets late-breaking ENDO 2026 slot - Stock Titan
ENTX Q1 2026 Earnings: Narrower-than-Expected Loss Reflects Cost Discipline Amid Pre-Revenue StageROA Comparison - newsline.com
ENTX - Finviz
Entera Bio Ltd. (ENTX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Strong Earnings BeatRevenue Estimate Trend - Newser
Entera Bio (ENTX) Q1 2026 Earnings: Narrowing Losses as Cash Burn Remains in FocusEarnings Revision Report - The Legal Advocate
Entera Bio (ENTX) Faces Selling Pressure as Stock Dips Below Key ResistancePrice Action Signals - newser.com
[EFFECT] Entera Bio Ltd. SEC Filing - Stock Titan
Entera Bio (NASDAQ: ENTX) registers 19.6M shares; $14.5M possible on warrant exercises - Stock Titan
Entera Bio Ltd.Ordinary Shares (NQ: ENTX - FinancialContent
Entera Bio (ENTX) shareholder vote set for July 14, 2026; 2.5M-share plan increase - Stock Titan
TradingKey - TradingKey
Number of shareholders of Entera Bio Ltd. – HAM:5DT - TradingView
MSN Money - MSN
Entera Bio Sees Funding Sufficient Through 1Q27 >ENTX - Moomoo
Entera Bio Highlights Q1 2026 Progress and Financing - TipRanks
Entera Bio (ENTX) grants COO 72,993 RSUs in lieu of cash bonus - Stock Titan
Entera Bio (ENTX) CFO receives 58,394 RSUs through A2Z Counseling Ltd. - Stock Titan
Entera Bio (ENTX) awards 87,591 RSUs to Chief of R&D Burshtein - Stock Titan
Entera Bio Ltd. (NASDAQ: ENTX) registers 19.6M shares for resale under S-3 - Stock Titan
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Entera Bio (ENTX) widens Q1 loss as R&D doubles and cash runway nears Q1 2027 - Stock Titan
Entera pushes an osteoporosis pill toward Phase 3 as cash hits $20.4M - Stock Titan
Entera Bio (NASDAQ: ENTX) details Q1 2026 loss and cash runway to 2027 - Stock Titan
Press Release: Entera Announces First Quarter 2026 Financial Results and Updates Across Its Oral Peptide Programs - Moomoo
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs - GlobeNewswire
How Entera Bio (ENTX) performance reflects its true potential (Smart Money Flows) 2026-05-06Verified Stock Signals - newser.com
Entera Bio (ENTX) upgraded to buy: Here's what you should know - MSN
Entera Bio (ENTX) to Release Earnings on Friday - MarketBeat
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know - sharewise.com
HC Wainwright Has Strong Estimate for Entera Bio Q1 Earnings - MarketBeat
What is HC Wainwright's Estimate for Entera Bio Q1 Earnings? - MarketBeat
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entera Bio Ltd Stock (ENTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ellis Sean | Director |
Mar 05 '26 |
Buy |
1.23 |
10,000 |
12,300 |
188,098 |
| Rubin Steven D | Director |
Feb 12 '26 |
Buy |
1.49 |
5,000 |
7,450 |
15,000 |
| Rubin Steven D | Director |
Feb 09 '26 |
Buy |
1.20 |
10,000 |
12,000 |
10,000 |
| Ellis Sean | Director |
Feb 09 '26 |
Buy |
1.24 |
18,000 |
22,320 |
178,098 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 29 '25 |
Buy |
1.81 |
11,000 |
19,912 |
426,575 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):